Results from the ongoing, open-label extension (OLE) study of the pivotal NEURO-TTR trial published in the European Journal of Neurology show that patients treated with TEGSEDI® (inotersen) experienced sustained improvements in measures of neuropathic progression at 39 months of therapy compared to the natural history of the disease.
Patients administered TEGSEDI also experienced clinically relevant improvements in measures of quality of life compared to the natural history of the disease.
No new safety signals were identified in the OLE study.
Company :-Akcea Therapeutics Inc.
User :- Akcea Therapeutics
Phone :-(617) 207-0202